Multiple Sclerosis Clinical Trials in Baltimore, Maryland
12 recruitingBaltimore, Maryland
Showing 1–12 of 12 trials
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Multiple SclerosisMultiple Sclerosis Fatigue
Johns Hopkins University46 enrolled1 locationNCT06170970
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.2,000 enrolled88 locationsNCT06433752
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled56 locationsNCT07074886
Recruiting
Not Applicable
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation60 enrolled6 locationsNCT06796504
Recruiting
Phase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Johns Hopkins University120 enrolled1 locationNCT07497399
Recruiting
Phase 4
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Multiple Sclerosis
Johns Hopkins University50 enrolled1 locationNCT07389590
Recruiting
Not Applicable
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Multiple Sclerosis (MS) - Relapsing-remitting
University of Maryland, Baltimore30 enrolled1 locationNCT06864936
Recruiting
Not Applicable
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
FatigueMultiple Sclerosis
Accelerated Cure Project for Multiple Sclerosis2,000 enrolled6 locationsNCT06441617
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 2
Ketamine for Multiple Sclerosis Fatigue
Multiple Sclerosis Fatigue
Johns Hopkins University110 enrolled1 locationNCT05378100
Recruiting
Phase 2
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD54 enrolled7 locationsNCT06292923